Qiagen steady ahead of earnings, shares watched by analysts

By Thomas Klein, Operations & Strategy desk. Reviewed prior to publication on 2026-06-29, 13:25.

Qiagen N.V. (NL0012169213) remains a core diagnostics and life-sciences name for international investors, with the stock primarily traded on the NYSE in New York. The next earnings release is expected later this summer based on the company's financial calendar, and analysts continue to track guidance and margin trends. Qiagen investor relations overview

Analysts follow Qiagen guidance

Qiagen has communicated medium-term ambitions around revenue growth and profitability, with the focus on consumables and instruments for molecular testing and sample preparation in clinical and research settings. Consensus data compiled by market platforms shows a majority of analysts keeping a neutral to positive stance on the stock, with a mix of Buy and Hold ratings and only a limited number of Sells. MarketScreener consensus summary for Qiagen

Research houses such as Goldman Sachs, JPMorgan and Deutsche Bank have historically covered Qiagen, commenting on the company's exposure to clinical diagnostics, applied testing and academic research markets, though no new rating change has been reported in very recent days. The stock remains linked to broader healthcare and life-sciences indices, offering exposure to molecular diagnostics demand trends and recurring consumables revenue streams. Reuters company profile and coverage on Qiagen

Earnings calendar and sector backdrop

Qiagen typically reports quarterly earnings around late July or early August for its second quarter, and investors watch closely for updates on instrument placements and consumables attach rates. The company's financial calendar on its investor-relations site lists upcoming events such as conference presentations and results releases, giving investors a framework for timing and expectations around new data points. Qiagen events and presentations schedule

Within life sciences, Qiagen competes and collaborates with peers including Thermo Fisher Scientific, Roche diagnostics and Bio-Rad Laboratories, all of which are exposed to trends in PCR testing, next-generation sequencing workflows and sample-processing tools. Sector performance in recent weeks has been shaped by investor views on healthcare spending, research budgets and reimbursement dynamics for diagnostic tests, factors that also influence Qiagen's medium-term revenue trajectory.

How Qiagen earns its money

Qiagen generates revenue by supplying molecular diagnostics and life-science research customers with consumables, instruments and software that enable sample preparation and nucleic-acid testing workflows. Key product families include QIAamp kits for DNA extraction, QIAcube and QIAcube Connect instruments for automated sample processing, and QIAstat-Dx systems for syndromic testing panels in infectious diseases.

Qiagen shares and listing

Qiagen shares trade on the NYSE under the ticker QGEN, quoted in US dollars, with additional trading on European venues via various platforms. As of 2026-06-29, 11:25, Qiagen shares were last quoted around 44.50 USD on the NYSE, reflecting a mid-cap healthcare valuation tied to recurring consumables revenues and installed instrument bases.

This article was produced with AI assistance and editorially reviewed. Price and company figures without guarantee; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Stock-market transactions carry risks up to and including total loss.